Biocaptiva is developing the Biocaptis, a revolutionary medical device which has the potential to transform liquid biopsy testing for cancer management, by improving early diagnosis and monitoring of disease and enhancing clinical trial data of cancer patients. The Biocaptis captures up to 100x more cell free DNA (cfDNA) than a venous blood draw, yielding cfDNA in high quality and quantity for testing, addressing the major challenge of liquid biopsy in cancer management. This will potentially allow the testing of a far greater number of cancer types and stages in a much wider range of patients. Biocaptiva was founded in 2021 when it spun out from the University of Edinburgh. Biocaptiva is based in Edinburgh and backed by Archangels, Scottish Enterprise, Cancer Research Horizons, the new innovation engine of Cancer Research UK, and Old College Capital, the University of Edinburgh’s in-house venture investment fund. For more information, please visit www.biocaptiva.com.
Something looks off?